These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

987 related articles for article (PubMed ID: 36066519)

  • 1. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
    JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
    Rodriguez LA; Finertie H; Neugebauer RS; Gosiker B; Thomas TW; Karter AJ; Gilliam LK; Oshiro C; An J; Simonson G; Cassidy-Bushrow AE; Dombrowski S; Nolan M; O'Connor PJ; Schmittdiel JA
    Lancet Reg Health Am; 2024 Jun; 34():100759. PubMed ID: 38745886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes.
    Chen WH; Li Y; Yang L; Allen JM; Shao H; Donahoo WT; Billelo L; Hu X; Shenkman EA; Bian J; Smith SM; Guo J
    PLoS One; 2024; 19(1):e0297208. PubMed ID: 38285682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
    McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
    JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice.
    Nanna MG; Kolkailah AA; Page C; Peterson ED; Navar AM
    JAMA Cardiol; 2023 Jan; 8(1):89-95. PubMed ID: 36322056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are There Differences in Postoperative Opioid Prescribing Across Racial and Ethnic Groups? Assessment of an Academic Health System.
    O'Sullivan LR; Shofer FS; Delgado MK; Agarwal AK; Humbyrd C
    Clin Orthop Relat Res; 2023 Aug; 481(8):1504-1511. PubMed ID: 36795497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial/Ethnic Disparities in the Performance of Prediction Models for Death by Suicide After Mental Health Visits.
    Coley RY; Johnson E; Simon GE; Cruz M; Shortreed SM
    JAMA Psychiatry; 2021 Jul; 78(7):726-734. PubMed ID: 33909019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.
    Mahtta D; Ramsey DJ; Lee MT; Chen L; Al Rifai M; Akeroyd JM; Vaughan EM; Matheny ME; Santo KRDE; Navaneethan SD; Lavie CJ; Birnbaum Y; Ballantyne CM; Petersen LA; Virani SS
    Diabetes Care; 2022 Feb; 45(2):372-380. PubMed ID: 35015080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial inequities in U.S. naloxone prescriptions.
    Madden EF; Qeadan F
    Subst Abus; 2020; 41(2):232-244. PubMed ID: 31718487
    [No Abstract]   [Full Text] [Related]  

  • 11. Associations between race and ethnicity and perioperative outcomes among women undergoing hysterectomy for adenomyosis.
    Meyer R; Maxey C; Hamilton KM; Nasseri Y; Barnajian M; Levin G; Truong MD; Wright KN; Siedhoff MT
    Fertil Steril; 2024 Jun; 121(6):1053-1062. PubMed ID: 38342374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State Variation in Racial and Ethnic Disparities in Incidence of Triple-Negative Breast Cancer Among US Women.
    Sung H; Wiese D; Jatoi I; Jemal A
    JAMA Oncol; 2023 May; 9(5):700-704. PubMed ID: 36862439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.
    Essien UR; Singh B; Swabe G; Johnson AE; Eberly LA; Wadhera RK; Breathett K; Vaduganathan M; Magnani JW
    JAMA Netw Open; 2023 Jun; 6(6):e2316290. PubMed ID: 37261826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
    Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA
    Front Public Health; 2022; 10():1031306. PubMed ID: 36408008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial and Ethnic Disparities in All-Cause and Cause-Specific Mortality Among US Youth.
    Wolf ER; Rivara FP; Orr CJ; Sen A; Chapman DA; Woolf SH
    JAMA; 2024 May; 331(20):1732-1740. PubMed ID: 38703403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Chu CD; Peralta CA; Du Y; Singh R; Kong SX; Tuot DS; Shlipak MG; Estrella MM
    Diabetes Care; 2022 Dec; 45(12):2900-2906. PubMed ID: 36156061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus.
    Zhang J; Van Spall HG; Li L; Khan MS; Pandey A; Thabane L; Bai X; Wang Y; Lip GY; Li G
    Diabetes Metab Syndr; 2023 Jul; 17(7):102804. PubMed ID: 37315473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.
    Blood AJ; Chang LS; Hassan S; Chasse J; Stern G; Gabovitch D; Zelle D; Colling C; Aronson SJ; Figueroa C; Collins E; Ruggiero R; Zacherle E; Noone J; Robar C; Plutzky J; Gaziano TA; Cannon CP; Wexler DJ; Scirica BM
    Circulation; 2024 Jun; 149(23):1802-1811. PubMed ID: 38583146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.
    Eberly LA; Yang L; Essien UR; Eneanya ND; Julien HM; Luo J; Nathan AS; Khatana SAM; Dayoub EJ; Fanaroff AC; Giri J; Groeneveld PW; Adusumalli S
    JAMA Health Forum; 2021 Dec; 2(12):e214182. PubMed ID: 35977298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial and Ethnic Disparities in the Prescribing of Pain Medication in US Primary Care Settings, 1999-2019: Where Are We Now?
    Thompson T; Stathi S; Shin JI; Carvalho A; Solmi M; Liang CS
    J Gen Intern Med; 2024 Jul; 39(9):1597-1605. PubMed ID: 38302811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.